Ronald Krauss, MD, of Children’s Hospital, Oakland, on the promise of reversing type 2 diabetes through a low carbohydrate (ketogenic) diet, with Virta. (00:21)”The good thing about it is it really makes sense from the standpoint of underlying mechanisms, that carbohydrates can aggravate hunger, they can put fat on to a greater extent than other kinds of food, and I think that the ketogenic approach is what’s really quite fascinating.”
Krauss is an advisor to Virta Health, an online specialty medical clinic that reverses type 2 diabetes—lowering HbA1c to non-diabetic range while eliminating diabetes medications. Virta’s clinically-proven intervention is based on technology-enabled continuous remote care delivered by licensed physicians and a unique individualized nutrition protocol emphasizing carbohydrate restriction and nutritional ketosis.
Ronald M. Krauss, MD, is senior scientist and director of atherosclerosis research at the Children’s Hospital Oakland Research Institute, and adjunct professor of medicine, University of California, San Francisco, and adjunct professor of nutritional sciences, University of California, Berkeley. He is also a Scientific Advisor to Virta Health.
Learn more about Virta’s clinical trial:
Meet our team:
Visit our site for more information on Virta:
YouTube Playlist: Meet our Virta Advisors
Follow Virta on Facebook
Follow Virta on Twitter
I think a low-carbohydrate diet is very attractive. It’s really based on, already, the evidence we have from studies in non-diabetic patients, reversing some of the metabolic traits that underly type 2 diabetes and also the preliminary data we’ve seen from Virta indicating benefit.
The good thing about it is it really makes sense from the standpoint of underlying mechanisms, that carbohydrates can aggravate hunger, they can put fat on to a greater extent than other kinds of foods.
And I think that the ketogenic approach is what’s really quite fascinating. To take the carbohydrate intake all the way down to generate ketones is something that’s been around for a long time. I think that showing that this can be effective in a real world clinical setting is a very promising approach to take. I think it’s going to be really interesting to see how this all plays out over time.